Detalhe da pesquisa
1.
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Blood
; 131(6): 611-620, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158362
2.
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.
Blood
; 127(3): 352-9, 2016 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26576864
3.
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
Blood
; 125(13): 2111-9, 2015 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25628467
4.
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.
Blood
; 121(18): 3759-67, 2013 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23471305
5.
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA.
Mol Cancer Ther
; 19(12): 2575-2584, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33082277
6.
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
Cancer Res
; 77(14): 3885-3893, 2017 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28566329
7.
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.
Cancer Res
; 76(22): 6669-6679, 2016 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27590740
8.
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
PLoS One
; 10(3): e0120561, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25785845
9.
In vivo localization of 9°Y and ¹77Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.
Cancer Res
; 74(20): 5846-54, 2014 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261237
10.
Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
PLoS One
; 9(12): e113601, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25460570
11.
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
Cancer Res
; 74(4): 1179-89, 2014 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24371230